Is Coherus Biosciences Inc (CHRS) Stock About to Get Hot Tuesday?

Coherus Biosciences Inc (CHRS) stock is lower by 10.14% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Coherus Biosciences Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on CHRS!

See Full CHRS Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With CHRS Stock Today?

Coherus Biosciences Inc (CHRS) stock is trading at $1.86 as of 9:52 AM on Tuesday, Nov 28, a loss of -$0.08, or -4.12% from the previous closing price of $1.94. The stock has traded between $1.86 and $1.93 so far today. Volume today is low. So far 98,641 shares have traded compared to average volume of 5,748,849 shares. To see InvestorsObserver's Sentiment Score for Coherus Biosciences Inc click here.

More About Coherus Biosciences Inc

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States. Click Here to get the full Stock Report for Coherus Biosciences Inc stock.